Cardiff Oncology, Inc. CRDF

CRDF Company Overview

Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on developing therapies for cancer treatment, with a primary emphasis on targeting polo-like kinase 1 (PLK1), a protein involved in tumor cell division and survival. The company operates within the oncology and biopharmaceutical industries and is publicly traded on Nasdaq under the ticker CRDF. Its core development program is onvansertib, an orally administered and highly selective PLK1 inhibitor being evaluated in combination therapies for several cancer indications, including metastatic colorectal cancer (mCRC), pancreatic cancer, and other solid tumors.

The company’s principal value driver is the advancement and commercialization potential of onvansertib through clinical development, strategic collaborations, and intellectual property associated with PLK1 inhibition. Cardiff Oncology has focused particularly on KRAS-mutated cancers, where unmet medical need remains significant despite recent advances in targeted therapies. The company originated as Trovagene, Inc., initially concentrating on molecular diagnostics before shifting its strategic focus toward oncology therapeutics through licensing and acquisition activities related to onvansertib. The company subsequently rebranded as Cardiff Oncology to reflect its therapeutic development orientation.